Leo Pharma receives UK approval for Adtralza

Efforts to receive approvals for Leo Pharma's eczema treatment Adtralza are continuing, and have now been rewarded by permission to launch the drug on the UK market.

Photo: Leo Pharma / PR

While Leo Pharma awaits news on the fate of Adtralza in the US in the wake of a rejection from the Food and Drug Administration (FDA) earlier in the year, the company has positive news from the United Kingdom.

In connection with the final approval given by the European Medicines Agency (EMA), the Danish firm has now also received authorization to market the drug in the UK from the Medicines and Healthcare products Regulatory Agency (MHRA).

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs